Antidepressant Monotherapy on Depressive and Anxiety Symptom in Chinese Patients
The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2013 by Shanghai Zhongshan Hospital.
Recruitment status was Recruiting
Information provided by (Responsible Party):
Shanghai Zhongshan Hospital
First received: November 15, 2013
Last updated: December 10, 2013
Last verified: December 2013
The primary objective is to evaluate the improvement of antidepressant monotherapy on depressive and anxiety symptom in Chinese patients who meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for the comorbidity of major depressive disorder (MDD) and generalized anxiety disorder (GAD)
Adverse Drug Reaction
Anxiety Disorders and Symptoms
||Observational Model: Case Control
Time Perspective: Retrospective
||Antidepressant Monotherapy on Depressive and Anxiety Symptom in Chinese Patients Who Meet Comorbidity of Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)
Primary Outcome Measures:
- Evaluate the score of HAMD17 (Hamilton Depression Rating Scale) and HAMA (Hamilton Anxiety Rating Scale) of patients in each time between two groups [ Time Frame: one year ] [ Designated as safety issue: Yes ]
The efficacy variables is include:
Onset rate: proportion of patient with at least 20% reduction in HAMD total score after 1 week Response rate: proportion of patient with at least 50% reduction in HAMD total score Remission rate: remission is defined as HAMD ≤ 7; remission rate is proportion of patients with remission HAMD total score change from baseline to week 6 and to week 24 (LOCF) during the study.
HAMA and the Mos36-item Short Form Health Survey (SF-36) score Change from baseline to week6 and to week 24 (LOCF) during the study.
Secondary Outcome Measures:
- Evaluate the symptom of depression, anxiety and quality of life in each time between two groups [ Time Frame: one year ] [ Designated as safety issue: Yes ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||January 2014 (Final data collection date for primary outcome measure)
venlafaxine or escitalopram
To evaluate the improvement of the quality of life of antidepressant monotherapy on Chinese patients who meet DSM-5 criteria for the comorbidity of MDD and GAD. To monitor adverse events (AEs) and serious adverse events (SAEs) of antidepressant monotherapy
|Ages Eligible for Study:
||18 Years to 65 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Chinese patients who meet DSM-5 criteria for the combidity of MDD and GAD
- First episode outpatients in department of psychiatry, aged 18-65 years
- Comorbidity of MDD and GAD according to DSM-5 criteria Hamilton Depression score (HAMD) of ≥18 at screening
- HAMA≥14 at screening
- Medically stable
- Provision of written, informed consent.
- Suicide ideation
- Use antidepressants within at least 14 days before study begin
- Substance or alcohol dependence at enrolment (except dependence in full remission, and except for caffeine or nicotine dependence)
- Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse within 4 weeks prior to enrolment
- Unstable or inadequately treated medical illness (e.g. congestive heart failure, angina pectoris, hypertension, renal or hepatic dysfunction, cerebrovascular disease ) as judged by the investigator
- Women in pregnancy or lactation
- Medical conditions that would affect absorption, distribution, metabolism or excretion of study treatment.
- Medical history with seizure disorder, except for febrile convulsion
- Participation in another clinical study within 4 weeks (or longer time according to the local requirement)
- Receive Electroconvulsive therapy (ECT) before study begin
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02012504
|Contact: Xiao Huang
||+862164041990 ext 3012
|Zhongshan Hospital, Fudan University
|Shanghai, Shanghai, China |
|Contact: Xiao Huang +862164041990 |
Shanghai Zhongshan Hospital
||Xiao Huang, MD
||Jian l Ji, MD
||Shanghai Zhongshan Hospital
History of Changes
|Other Study ID Numbers:
|Study First Received:
||November 15, 2013
||December 10, 2013
||China: Ethics Committee
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on April 27, 2016
Drug-Related Side Effects and Adverse Reactions
Central Nervous System Agents